Bruker Bruker is a company that develops, manufactures, and distributes scientific instruments and analytical and diagnostic services. | GE HealthCare Technologies GE HealthCare Technologies is a medical technology company that provides pharmaceutical diagnostics and digital solutions. | Thermo Fisher Scientific Thermo Fisher Scientific is a biotechnology company engaged in service science. | Revvity Revvity (formerly PerkinElmer) is a company that provides products, services, and solutions for the diagnostics, life sciences, and applied markets. | Shimadzu Shimadzu (株式会社島津製作所) is a company that manufactures analytical measuring instruments, medical imaging systems, vacuum industry machinery, hydraulic equipment, aircraft equipment, and optical devices. | ||||
Founding Date | Founding Date 1960 | Founding Date 1986 | Founding Date 1958 | Founding Date 1892 | Founding Date 1984 | Founding Date 1956 | Founding Date 1937 | Founding Date 1875 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||
Locations | Locations London, GB HQ | Locations Milford, US HQ Rydalmere, AU Wien, AT Antwerpen, BE Sao Paulo, BR Brossard, CA Mississauga, CA see more | Locations Chicago, US HQ El Biar, DZ Parramatta, AU Tiefenbach, AT Wien, AT Machelen, BE Contagem, BR see more | Locations Washington, US HQ Mount Waverley, AU Vienna, AT Ghent, BE Sao Paolo, BR Vancouver, CA Shanghai, CN see more | Locations Waltham, US HQ Buenos Aires, AR Buenos Aires, AR Buenos Aires, AR Adelaide Airport, AU Brendale, AU Canberra, AU see more | Locations Waltham, US HQ Melbourne, AU Lier, BE São Paulo, BR Mississauga, CA Shanghai, CN Ballerup, DK see more | Locations Kyoto, JP HQ Sydney, AU Korneuburg, AT Wemmel, BE Sarajevo, BA Porto Alegre, BR Rio De Janeiro, BR see more | |
Employees | Employees 9,70714% increase | Employees 7,0004% decrease | Employees 7,9004% decrease | Employees 50,000 | Employees 61,00023% decrease | Employees 122,0006% decrease | Employees 16,700 | Employees 14,6163% increase |
Valuation ($) | Valuation ($) 10.1 b | Valuation ($) 3.4 b | Valuation ($) 21.3 b | Valuation ($) 41.7 b | Valuation ($) 198.3 b | Valuation ($) 229.5 b | Valuation ($) 15.8 b | Valuation ($) 9.7 b |
Financial | ||||||||
Revenue (est.) | Revenue (est.) $3b (FY, 2023) | Revenue (est.) £1.4b (FY, 2023) | Revenue (est.) $3b (FY, 2023) | Revenue (est.) $19.6b (FY, 2023) | Revenue (est.) $23.9b (FY, 2023) | Revenue (est.) $42.9b (FY, 2023) | Revenue (est.) $2.8b (FY, 2023) | Revenue (est.) ¥511.9b (FY, 2024) |
Cost of goods | Cost of goods $1.5b (FY, 2023) | Cost of goods £553.4m (FY, 2023) | Cost of goods $1.2b (FY, 2023) | Cost of goods $11.6b (FY, 2023) | Cost of goods $9.9b (FY, 2023) | Cost of goods $25.8b (FY, 2023) | Cost of goods N/A | Cost of goods ¥272.5b (FY, 2024) |
Gross profit | Gross profit $1.5b (FY, 2023) | Gross profit £895.8m (FY, 2023) | Gross profit $1.8b (FY, 2023) | Gross profit $7.9b (FY, 2023) | Gross profit $14b (FY, 2023) | Gross profit $17.1b (FY, 2023) | Gross profit N/A | Gross profit ¥239.4b (FY, 2024) |
Net income | Net income $428.5m (FY, 2023) | Net income £145.4m (FY, 2023) | Net income $642.2m (FY, 2023) | Net income $1.6b (FY, 2023) | Net income $4.2b (FY, 2023) | Net income $6b (FY, 2023) | Net income $693.1m (FY, 2023) | Net income ¥57b (FY, 2024) |
Operating ⚠ | ||||||||
Backlog | Backlog $2.1b (FY, 2022) | Backlog N/A | Backlog N/A | Backlog $17b (Q1, 2021) | Backlog N/A | Backlog N/A | Backlog N/A | Backlog N/A |
Countries | Countries N/A | Countries 30 (FY, 2023) | Countries N/A | Countries 17 (FY, 2022) | Countries 50 (FY, 2023) | Countries 70 (FY, 2023) | Countries N/A | Countries N/A |
Facilities | Facilities N/A | Facilities N/A | Facilities 92 (FY, 2023) | Facilities 336 (FY, 2022) | Facilities 184 (FY, 2023) | Facilities N/A | Facilities N/A | Facilities N/A |
Facilities (US) | Facilities (US) N/A | Facilities (US) N/A | Facilities (US) 21 (FY, 2023) | Facilities (US) N/A | Facilities (US) 70 (FY, 2023) | Facilities (US) N/A | Facilities (US) N/A | Facilities (US) N/A |
Remaining Performance Obligations | Remaining Performance Obligations $2.3b (FY, 2022) | Remaining Performance Obligations N/A | Remaining Performance Obligations N/A | Remaining Performance Obligations $14.2b (Q3, 2023) | Remaining Performance Obligations $4.5b (Q2, 2024) | Remaining Performance Obligations $26.4b (Q1, 2024) | Remaining Performance Obligations N/A | Remaining Performance Obligations N/A |
Sales Representatives | Sales Representatives N/A | Sales Representatives N/A | Sales Representatives 4.3 k (FY, 2023) | Sales Representatives N/A | Sales Representatives N/A | Sales Representatives N/A | Sales Representatives 6.3 k (FY, 2022) | Sales Representatives N/A |
Funding | ||||||||
Total funding raised | Total funding raised $ 24.5m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 500m | Total funding raised $ 2.2b | Total funding raised N/A |